ASCO Virtual Meeting Program - MD Anderson Cancer Center
MD Anderson at the 2020 ASCO Annual Meeting
May 29-31, 2020
MD Anderson Cancer Center Presentations at 2020 ASCO Annual Meeting
STREAMING PRESENTATIONS
Saturday, May 30
1:00 ? 2:30 p.m. EDT
Special Clinical Science
Symposium
Harnessing Immunotherapy with Novel
Discussion: Tumor-Specific Vaccines: Lessons Learned from HPV
Approaches Beyond Checkpoint Inhibitors
Michael A. Curran, Ph.D.
1:00 ? 2:30 p.m. EDT
Special Clinical Science Symposium
102: Phase I dose escalation and expansion trial to assess the safety and efficacy of ADP-A2M4 SPEAR T cells in advanced David S. Hong, M.D.
Harnessing Immunotherapy with Novel solid tumors
Approaches Beyond Checkpoint Inhibitors
Sunday, May 31
10:30 a.m. ? 12:00 p.m. EDT
Special Clinical Science Symposium
Drug Development for Rare Mutations: The Opportunity to Unite and Conquer!
109: Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors
Vivek Subbiah M.D.
1:00 ? 3:00 p.m. EDT
Plenary Session
Discussion of LBA4: Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 study
Michael J. Overman, M.D.
2
MD Anderson Cancer Center Presentations at 2020 ASCO Annual Meeting
ON-DEMAND CLINCAL SCIENCE SYMPOSIUM PRESENTATIONS
Tumor Intrinsic and Extrinsic Factors Affecting Immunotherapy Response in Head and Neck Cancer
Discussion: Of Bugs and Drugs: How Our Microbiome Saves Us
Ann Klopp, M.D., Ph.D.
ON-DEMAND ORAL PRESENTATIONS
Cancer Prevention, Risk Reduction, and Genetics
Discussion: Seek and Ye Shall Find: Germline Mutations in Somatic Profiling
Funda Meric-Bernstam, M.D.
Developmental Therapeutics-- 3008: Correlation of pathogenic POLE mutations with clinical benefit to
Immunotherapy
immune checkpoint inhibitor therapy.
Benjamin Garmezy, M.D.
Developmental Therapeutics-- Discussion: Using Genomics to Select for Checkpoint Blockade Immunotherapy
Ferdinandos Skoulidis, M.D., Ph.D.
Developmental Therapeutics-- Molecularly Targeted Agents and Tumor Biology
3506: Phase II study of copanlisib in patients with tumors with PIK3CA mutations (PTEN loss allowed): NCI MATCH EAY131-Z1F.
Senthil Damodaran, M.D. Ph.D.
Gastrointestinal Cancer-- Colorectal and Anal
4001: Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).
Scott Kopetz, M.D. Ph.D.
Genitourinary Cancer--Kidney and Bladder
5003: Phase II study of the oral HIF-2 inhibitor MK-6482 for Von HippelLindau disease?associated renal cell carcinoma.
Eric Jonasch, M.D.
Genitourinary Cancer--
5504: Neoadjuvant apalutamide (APA) plus leuprolide (LHRHa) with or
Prostate, Testicular, and Penile without abiraterone (AA) in localized high-risk prostate cancer (LHRPC).
Eleni Efstathiou, M.D. Ph.D.
Hematologic Malignancies-- 7500: Phase Ib/II study of the IDH1-mutant inhibitor ivosidenib with the
Leukemia, Myelodysplastic
BCL2 inhibitor venetoclax +/- azacitidine in IDH1-mutated hematologic
Syndromes, and Allotransplant malignancies.
Curtis Lachowiez, M.D.
3
MD Anderson Cancer Center Presentations at 2020 ASCO Annual Meeting
Hematologic Malignancies-- 7501: Effect of enasidenib (ENA) plus azacitidine (AZA) on complete
Leukemia, Myelodysplastic
remission and overall response versus AZA monotherapy in mutant-
Syndromes, and Allotransplant IDH2 (mIDH2) newly diagnosed acute myeloid leukemia (ND-AML).
Courtney Dinardo M.D.
Hematologic Malignancies-- 7508: Updated results from phase I dose-escalation study of AMG 330, a
Leukemia, Myelodysplastic
bispecific T-cell engager molecule, in patients with relapsed/refractory
Farhad Ravandi, M.D.
Syndromes, and Allotransplant acute myeloid leukemia (R/R AML).
Hematologic Malignancies-- Lymphoma and Chronic Lymphocytic Leukemia
8002: First-in-human data of ALLO-501 and ALLO-647 in relapsed/refractory large B-cell or follicular lymphoma (R/R LBCL/FL): ALPHA study.
Sattva Neelapu, M.D.
Hematologic Malignancies-- Plasma Cell Dyscrasia
Discussion: Guns N' Roses: CAR T in Multiple Myeloma
Krina K. Patel, M.D.
Lung Cancer--Non-Small Cell Discussion: Limited-Stage Small Cell Lung Cancer: Have We Finally
Local-Regional/Small Cell/Other Thoracic Cancers
Defined Radiation Standards?
Melanoma/Skin Cancers
10008: Single-center phase I/Ib study of concurrent intrathecal (IT) and intravenous (IV) nivolumab (N) for metastatic melanoma (MM) patients (pts) with leptomeningeal disease (LMD).
Percy Lee, M.D. Isabella Glitza, M.D. Ph.D.
Melanoma/Skin Cancers
Discussion: Adjuvant and Neoadjuvant Therapies in 2020
Rodabe Amaria, M.D.
Pediatric Oncology I Sarcoma Symptoms and Survivorship
10508: Phase II study of antidisialoganglioside antibody, dinutuximab, in
combination with GM-CSF in patients with recurrent osteosarcoma
Pooja Hingorani, M.D.
(AOST1421): A report from the Children's Oncology Group.
11505: Preliminary results of a phase II study of neoadjuvant checkpoint blockade for surgically resectable undifferentiated pleomorphic sarcoma Christina Roland, M.D. (UPS) and dedifferentiated liposarcoma (DDLPS).
12006: Neuroleptic rotation for refractory agitation in cancer patients with
delirium in the acute palliative care unit: A double-blind randomized
David Hui, M.D.
clinical trial.
4
MD Anderson Cancer Center Presentations at 2020 ASCO Annual Meeting
ON-DEMAND POSTER DISCUSSION PRESENTATIONS
Breast Cancer-- Local/Regional/Adjuvant
509: Immune phenotype and response to neoadjuvant systemic therapy (NAST) in triple negative breast cancer (TNBC).
Clinton Yam, M.D.
Breast Cancer-- Local/Regional/Adjuvant
Breast Cancer--Metastatic
517: Comprehensive profiling of androgen receptor-positive (AR+) triple-
negative breast cancer (TNBC) patients (pts) treated with standard
Bora Lim, M.D.
neoadjuvant therapy (NAT) +/- enzalutamide.
1018: Exploring impact of mutations in non-BRCA DNA damage response
(DDR) and non-DDR genes on efficacy in phase III EMBRACA study of talazoparib (TALA) in patients (pts) with germline BRCA1/2 mutated
Jennifer Litton, M.D.
(gBRCAm) HER2-negative (HER2-) advanced breast cancer (ABC).
Care Delivery and Regulatory Discussion: Using Patient-Reported Outcomes to Inform Clinical Trials
Policy
and Clinical Practice
Ishwaria M. Subbiah, M.D.
Care Delivery and Regulatory Policy
2020 : Absence of optimism bias in industry-sponsored cancer trials.
Sonal Noticewala, M.D.
Central Nervous System Tumors
2511: Phase I/II study to evaluate the safety and clinical efficacy of atezolizumab (atezo; aPDL1) in combination with temozolomide (TMZ) and radiation in patients with newly diagnosed glioblastoma (GBM).
Shiao-Pei Weathers, M.D.
Central Nervous System Tumors
2515: A phase I/II clinical trial of autologous CMV-specific T cells in glioblastoma (GBM) patients to reveal a lack of immune effector function.
Shiao-Pei Weathers, M.D.
Developmental Therapeutics-- 3511: CodeBreak 100: Phase I study of AMG 510, a novel
Molecularly Targeted Agents KRASG12C inhibitor, in patients (pts) with advanced solid tumors other
and Tumor Biology
than non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).
David S. Hong, M.D.
Genitourinary Cancer--Kidney 5015 : ERDAFITINIB in locally advanced or metastatic urothelial
and Bladder
carcinoma (mUC): Long-term outcomes in BLC2001.
Arlene O. Siefker-Radtke, M.D.
Genitourinary Cancer-- Prostate, Testicular, and Penile
Discussion: Promising Therapeutic Targets in Prostate Cancer
Ana Aparicio, M.D.
5
................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related download
- asco annual meeting to highlight clinical oncology findings from
- annual meeting poster agenus the right combination
- affimed highlights study design of its afm13 redirect trial at the asco
- volitionrx to present first data on nu q capture performance asco
- tumor methylation patterns accurately measure tumor fraction in grail
- 2020 asco annual meeting the lancet
- 2020 virtual annual meeting program draft histiocyte society
- asco virtual annual meeting 2020 swog
- american society of clinical oncology asco virtual scientific program
- md anderson researchers present cellular therapy advances at the asco
Related searches
- hardin memorial cancer center elizabethtown
- stanford cancer center palo alto
- asco 2020 annual meeting registration
- asco annual meeting 2020 agenda
- asco 2019 annual meeting agenda
- asco annual meeting registration
- asco annual meeting 2020 dates
- asco annual meeting 2019 abstracts
- asco 2020 meeting dates
- md anderson bladder cancer protocol
- asco 2020 meeting library
- asco 2020 meeting chicago